ICCC IMMUCELL CORP /DE/
Data as of close
Healthcare · In Vitro & In Vivo Diagnostic Substances
IMMUCELL CORP /DE/ (ICCC) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $96 million. Shares last traded at $10.55, 13.5% below their 52-week high. Over the past year the stock is up 71.5%. ICCC trades at a price-to-earnings ratio of 121.69, above the In Vitro & In Vivo Diagnostic Substances median of 34.57. Net profit margin is 2.6%, above the peer median of -1.9%. Revenue grew 4.3% year over year.
* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.
Performance
Chart
Full chart →Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.
Technicals
Financials
Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q2 2026 | $0.20 | 2026-08-13 |
| Q1 2026 | $0.21 | 2026-05-14 |
| Q4 2025 (derived) | -$0.32 | 2026-03-30 |
| FY 2025 | -$0.12 | 2026-03-30 |
| Q3 2025 | -$0.02 | 2025-11-13 |
| Q2 2025 | $0.06 | 2025-08-14 |
Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.
In Vitro & In Vivo Diagnostic Substances peers
ICCC vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Data as of close
| IDXX | Idexx Laboratories | $52.9B | 44.76 | 11.35 | 25.4% | +21.78% |
| LNTH | Lantheus Holdings, Inc. | $6.5B | 23.79 | 4.21 | 17.7% | -0.15% |
| NEOG | Neogen Corp | $2.6B | — | 2.92 | -6.3% | +0.17% |
| CLDX | Celldex Therapeutics, Inc. | $2.3B | — | 1476.05 | — | -3.49% |
| NTLA | Intellia Therapeutics, Inc. | $1.6B | — | — | — | -6.50% |
| QDEL | Quidelortho Corp | $962M | — | 0.36 | -39.2% | +6.05% |
| ACHV | Achieve Life Sciences, Inc. | $679M | — | — | — | -3.65% |
| MYGN | Myriad Genetics Inc | $557M | — | 0.69 | -14.0% | -8.13% |
| TKNO | Alpha Teknova, Inc. | $376M | — | 8.59 | -38.4% | -4.70% |
| NNNN | Anbio Biotechnology | $156M | 24.38 | 18.06 | 74.1% | +2.73% |
| ICCC | IMMUCELL CORP /DE/ | $96M | 121.69 | 3.12 | 2.6% | -0.42% |
| IMDX | Insight Molecular Diagnostics Inc. | $94M | — | 23.08 | — | -3.70% |
| BMRA | BIOMERICA INC | $8M | — | — | — | -0.58% |
| CDIO | Cardio Diagnostics Holdings, Inc. | $5M | — | 329.74 | — | -5.29% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.